[go: up one dir, main page]

WO2024233847A3 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use - Google Patents

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use Download PDF

Info

Publication number
WO2024233847A3
WO2024233847A3 PCT/US2024/028688 US2024028688W WO2024233847A3 WO 2024233847 A3 WO2024233847 A3 WO 2024233847A3 US 2024028688 W US2024028688 W US 2024028688W WO 2024233847 A3 WO2024233847 A3 WO 2024233847A3
Authority
WO
WIPO (PCT)
Prior art keywords
myeloid cells
receptor expressed
agonists
methods
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/028688
Other languages
French (fr)
Other versions
WO2024233847A2 (en
Inventor
Jonathan B. Houze
Bhaumik PANDYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vigil Neuroscience Inc
Original Assignee
Vigil Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vigil Neuroscience Inc filed Critical Vigil Neuroscience Inc
Publication of WO2024233847A2 publication Critical patent/WO2024233847A2/en
Publication of WO2024233847A3 publication Critical patent/WO2024233847A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure provides compounds useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
PCT/US2024/028688 2023-05-10 2024-05-09 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use Pending WO2024233847A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363501392P 2023-05-10 2023-05-10
US63/501,392 2023-05-10

Publications (2)

Publication Number Publication Date
WO2024233847A2 WO2024233847A2 (en) 2024-11-14
WO2024233847A3 true WO2024233847A3 (en) 2025-05-15

Family

ID=93431101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/028688 Pending WO2024233847A2 (en) 2023-05-10 2024-05-09 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Country Status (1)

Country Link
WO (1) WO2024233847A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12459952B2 (en) 2024-01-04 2025-11-04 Muna Therapeutics Aps TREM2 modulators
US12459953B2 (en) 2024-01-04 2025-11-04 Muna Therapeutics Aps TREM2 modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677352B1 (en) * 2001-09-26 2004-01-13 Yamin Wang 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders
WO2009097287A1 (en) * 2008-02-01 2009-08-06 Irm Llc Compounds and compositions as kinase inhibitors
US10548899B2 (en) * 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677352B1 (en) * 2001-09-26 2004-01-13 Yamin Wang 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders
WO2009097287A1 (en) * 2008-02-01 2009-08-06 Irm Llc Compounds and compositions as kinase inhibitors
US10548899B2 (en) * 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE Compound 8 February 2007 (2007-02-08), "5,8-dimethyl-6-(triazolo[4,5-c]pyridin-1-yl)-2H-isoquinolin-1-one", XP093326386, Database accession no. 12831685 *

Also Published As

Publication number Publication date
WO2024233847A2 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
PH12022552949A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
PH12022552933A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2022236272A3 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
US12213965B2 (en) Riluzole prodrugs and their use
WO2024233847A3 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
MX2007007220A (en) Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders.
ES2977656T3 (en) KDM1A inhibitors for the treatment of diseases
AU2021323253A8 (en) Heterocyclic GLP-1 agonists
UA85576C2 (en) Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
MXPA05010824A (en) Bicyclic compounds as nr2b receptor antagonists.
WO2024008722A3 (en) Trem2 modulators
EP1725536B8 (en) Imidazoline derivatives having cb1-antagonistic activity
MX2025002166A (en) Compounds and methods for modulating her2
WO2021224680A8 (en) Substituted benzotriazinone metabolites of a gpr139 agonist
CA3156320A1 (en) 2-azaspiro[3.4]octane derivatives as m4 agonists
PH12022550860A1 (en) 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists
US20220396555A1 (en) Prodrugs of riluzole and their method of use
EP4599849A3 (en) Novel inhibitors of autotaxin
RU2813145C2 (en) Lysine-specific histone demethylase 1a (kdm1a) inhibitors for disease therapy
MX2025013377A (en) 5,6-fused bicyclic amides and compositions for use as 15-prostaglandin dehydrogenase modulators
MX2025013369A (en) 5,6-fused and 6,6-fused bicyclic alcohols and ethers and compositions for use as 15-prostaglandin dehydrogenase modulators
UA84737C2 (en) Imidazoline derivatives having cb1-antagonistic activity
MY136600A (en) Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24804298

Country of ref document: EP

Kind code of ref document: A2